The herpes simplex virus type 1 ribonucleotide reductase is required for acute retinal disease

Archives of Virology

Volumn 142, Issue 5, 1997, Pages 883-896

  Brandt, C R ^a,b   Imesch, P ^a   Spencer, B ^a   Eliassi Rad, B ^a   Syed, N A ^a   Untawale, S ^a   Robinson, N L ^a   Albert, D M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBONUCLEOTIDE REDUCTASE; VIRUS ANTIGEN;

ACUTE DISEASE; ANIMAL; ARTICLE; ENZYMOLOGY; FEMALE; GENETICS; HERPES SIMPLEX VIRUS 1; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MOUSE STRAIN; MUTATION; PATHOGENICITY; PATHOLOGY; RETINITIS; VIROLOGY; VIRULENCE; VIRUS REPLICATION;

ACUTE DISEASE; ANIMALS; ANTIGENS, VIRAL; FEMALE; HERPESVIRUS 1, HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED STRAINS; MUTATION; RETINITIS; RIBONUCLEOTIDE REDUCTASES; VIRULENCE; VIRUS REPLICATION;

EID: 0031021047     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007050050126     Document Type: Article

References (23)

1. Brandt CR, Grau DR (1990) Mixed infection with HSV-1 generates recombinants with increased ocular and neurovirulence. Invest Ophthalmol Vis Sci 31: 2214-2223
2. Brandt CR, Kintner RL, Pumfery AM, Visalli RJ, Grau DR (1991) The herpes simplex virus ribonucleotide reductase is required for ocular virulence. J Gen Virol 72: 2043-2049
3. Brandt CR, Spencer B, Imesch P, Garneau M, Déziel R (1996) Evaluation of a peptido-mimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease. Antimicrob Agents Chemother 40: 1078-1084
4. Bridges CG, Ahmed SP, Sunkara PS, McCarthy JR, Tyms AS (1995) The ribonucleotide reductase inhibitor (E)-2′-fluoromethylene-2′-deoxycytidine (MDL 101, 731): a potent topical therapy for herpes simplex virus infection. Antiviral Res 27: 325-334
5. Cameron JM, McDougall, Marsden HS, Preston VG, Ryan DM, Subak-Sharpe JH (1988) Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target. J Gen Virol 69: 2607-2612
6. Cousins SW, Altman NH, Atherton SS (1989) Schisis contributes to necrosis in experimental HSV-1 retinitis. Exp Eye Res 48: 745-760
7. Chiocca EA, Choi BB, Cai W, DeLuca NA, Schaffer PA, DiFiglia M, Breakfield XO, Martuza RL (1990) Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. New Biol 2: 739-746
8. Dobson AT, Margolis TP, Sedarati F, Stevens JG, Feldman LT (1990) A latent nonpathogenic HSV-1 derived vector stably expresses β-galactosidase in mouse neurons. Neuron 5: 353-360
9. Farell HE, McLean CS, Havly C, Efstathiou S, Inglis S, Minsonot AS (1994) Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J Virol 68: 927-932
10. Fink DJ, Sternberg LR, Weber PC, Mata M, Goins WF, Glorioso JC (1992) In vivo expression of β-galactosidase in hippocampal neurons by HSV-mediated gene transfer. Human Gene Ther 3: 11-19
11. Goldstein DJ, Weller SK (1988) Factor(s) present in herpes simplex virus type-1 infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 166: 41-51
12. Grau DR, Visalli RJ, Brandt CR (1989) Herpes simplex virus stromal keratitis is not titer-dependent and does not correlate with neurovirulence. Invest Ophthalmol Vis Sci 30: 2474-2480
13. Hemady R, Opremcak EM, Zaltas M, Berger A, Foster CS (1989) Herpes simplex virus type 1 strain influence on chorioretinal disease patterns following intracameral inoculation in Igh-1 disparate mice. Invest Ophthalmol Vis Sci 30: 1750-1757
14. Idowu AD, Fraser-Smith EB, Poffenberger KL, Herman RC (1992) Deletion of the herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vivo. Antiviral Res 17: 145-156
15. Jacobson JG, Leib DA, Goldstein DJ, Bogard CL, Schaffer PA, Weller SK, Coen DM (1989) A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 173: 276-283
16. Liu Y, Sakai Y, Minagawa H, Toh Y, Ishibashi T, Inomata H, Mori R (1993) Induction of bilateral retinal necrosis in mice by unilateral intracameral inoculation of a glycoprotein-C deficient clinical isolate of herpes simplex virus type-1. Arch Virol 129: 105-118
17. Liuzzi M, Déziel R, Moss N, Beaulieu P, Bonneau A-M, Bousquet C, Chafouleas JG, Garneau M, Jaramillo J, Krogsrud RL, Lagace L, McCollum RS, Nawoot S, Guindon Y (1994) A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature 372: 695-698
18. Lokensgard JR, Bloom DC, Dobson AT, Feldman LT (1994) Long-term promoter activity during herpes simplex virus latency. J Virol 68: 7148-7158
19. Morrison LA, Knipe DM (1994) Immunization with replication defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol 68: 689-696
20. Spector T, Harrington JA, Morrison RW, Lambe CU, Nelson DJ, Averett DR, Biron K, Furman, PA (1989) 2-Acetylpyridine 5-[(dimethylamino)thio carbocyl]-thiocarbonohydrazone (A111OU), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir. Antimicrob Agents Chemother 36: 934-937
21. Thelander L, Reichard P (1979) Reduction of ribonucleotides. Annu Rev Biochem 48: 133-158
22. Whittum-Hudson JA, Merges MJ, Field HJ (1987) Immunogenicity versus pathogenicity after anterior chamber inoculation of an acyclovir-induced double mutant of HSV-1. Curr Eye Res 6: 1459-1470
23. Yamada Y, Kimura H, Morishima T, Daikodu T, Maeno K, Michiyama Y (1991) The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type 1 in mice. J Infect Dis 164: 1091-1097